Aflibercept 8 mg is the third commercially available second-generation VEGF inhibitor, circulated in 2024, following brolucizumab and faricimab; however, limited information regarding the loading phase of aflibercept 8 mg for exudative AMD is available. This evidence concerns the gene VEGFA and age-related macular degeneration.